Peer-influenced content. Sources you trust. No registration required. This is HCN.

Cancer Therapy AdvisorMetastatic Breast Cancer: Phase 3 Studies Herald More Options for Metastatic Breast Cancer

Presented at SABCS 2021, the EMERALD Study of elacastrant and the PHOEBE Trial of pyrotinib showed a better than doubling of 12-month PFS with the first agent, and an improvement in both OS and PFT with the second agent. And the results of the DESTINY-Breast03 study have been called “practice changing.”